author-photo

Enric Carcereny

Autonomous University of Barcelona

194

Papers

10468

Citations

Citation Trend

Filter By

Papers (138) Sort By

Journal Conference Others

Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver.

2021 Oncotarget
Show All
- Source
- Cite
- Save
Citations (0)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
P52.05 Lung Cancer Symptoms at Diagnosis: Data from the Thoracic Tumors Registry (TTR Study).

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
50P A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non–Small-Cell Lung Cancer

2021
Show All
- Source
- Cite
- Save
Citations (4)
Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer

2021 Cancers
Show All
- Source
- Cite
- Save
Citations (0)
1168P Clinical characteristics and survival in stage I-IIIA lung cancer resected patients in Spain, analyzed in the Thoracic Tumors Registry (TTR)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
359 Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic 2nd line head and neck squamous cell carcinoma (HNSCC)

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
1658P Clinical characteristics of long-term survivors (LTS) in small cell lung cancer (SCLC) patients (p) with extended disease (ED)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)